lytica type Al 7 days later. The majority of untreated lambs and lambs which had received either 200 ml of antiserum to P. haemolytica or 200 ml of control serum intraperitoneally 18 h before infection with P. haemolytica type Al succumbed to the challenge. Lymphocytes from vaccinated lambs showed a specific proliferative response when exposed to P. haemolytica type Al sodium salicylate extract, and this response increased after exposure of these animals to P. haemolytica type Al in aerosol. The results indicate that the humoral immune response alone is incapable of affording protection against experimental pasteurellosis and that cell-mediated immunity may play an important part in resistance to this disease.
The development of an experimental model of pneumonic pasteurellosis in specific-pathogenfree (SPF) lambs (6) has provided a more dependable means of assessing protective immunity conferred by Pasteurella vaccines. Previously, assessment of the efficacy of vaccines to Pasteurella haemolytica was based largely upon serological criteria, in particular upon the indirect hemagglutination (IHA) test for the detection of antibodies. However, there is no evidence to suggest that measurement of serum antibody titers to P. haemolytica gives any indication of the worth of vaccines in preventing disease in sheep. Correlation has been demonstrated between serum IHA titers in lambs vaccinated against P. haemolytica biotype A, serotype 1 (type Al) and the protective capacity of these sera when given passively to mice (N. J. L. Gilmour, D. A. Thompson, and D. Mould, manuscript in preparation). However, the resistance of individual vaccinated lambs to challenge with P. haemolytica type Al does not correlate with either of these parameters. Consequently, the role of humoral immunity in protection against P. haemolytica infection is unclear.
This paper describes an investigation of the efficacy of passively acquired antibody to P. haemolytica type Al on pneumonia induced by the challenge of SPF lambs with a combined infection of parainfluenza type 3 (PI3) virus and P. haemolytica type Al (6) . Data of specific proliferative responses of peripheral blood lymphocytes are also presented.
MATERIALS AND METHODS
Sheep. Twenty-seven hysterectomy-derived, colostrum-deprived lambs were reared under SPF conditions. These lambs were allocated to two groups of eight lambs, a third group of seven lambs, and a fourth group of four lambs.
Vaccine. Sodium salicylate extract (SSE) from P. haemolytica type Al, prepared as described elsewhere (Gilmour et Table 1 . At 2 weeks of age the eight lambs in group 1 were vaccinated with 2 ml of the P. haemolytica vaccine given subcutaneously over the sternum. Lambs in groups 2 and 3 were not treated at this time. Three weeks later the lambs in all three groups were inoculated intratracheally and intranasally with 1075 50% tissue culture infective dose (TCID50) PI3 virus (10) . Six days after infection with P13 virus, the lambs in group 2 each received 200 ml of antiserum to P. haemolytica type Al and the lambs in group 3 each received 20 ml of control serum. In each case, the serum was administered by intraperitoneal injection in two doses of 100 ml, the second given ca. 6 h after the first. Eighteen hours after the second injection, blood samples were collected from all lambs before groups 1, 2, and 3 were exposed to an aerosol of P. haemolytica type Al (3) which contained 3 x 103 organisms per liter. The lambs in group 4 were neither vaccinated nor infected with either P13 virus of P. haemolytica.
Lymphocyte cultures. Peripheral blood lymphocytes from four lambs in both the vaccinated and unvaccinated groups were obtained and cultured before vaccination and thereafter at intervals during the 4-week period until exposure to the aerosol of P. haemolytica type Al. Further cultures were prepared from the same lambs immediately before infection with P. haemolytica type Al and 3 and 5 days after infection. The lambs in group 4 which were not infected with either PI3 virus or P. haemolytica were sampled on these latter three occasions. Lymphocytes were prepared and cultured as described previously (1) , with the exception that the culture medium contained 5 x 10-' M 2-mercaptoethanol (4) and cultures were maintained for a period of 5 Clinical responses. Lambs in groups 1, 2, and 3 which were infected with P13 virus developed the clinical signs of pyrexia, dyspnoea, anorexia, and dullness described previously as associated with this infection (11) . After exposure to the aerosol of P. haemolytica, lambs in the vaccinated group showed no sign of clinical illness except a slight pyrexia in two individuals on the day after infection. In contrast, four of the seven lambs in group 3 treated with negative control serum were dull and seven of the eight lambs in group 2 treated with antiserum to P. haemolytica showed pyrexia and dullness during the 5 days after infection with P. haemolytica. Dyspnoea was observed only in the unvaccinated control and antiserum-treated lambs in groups 2 and 3. The two lambs which did not appear to have absorbed antibody in the group treated with antiserum exhibited more marked clinical signs than did the other lambs in this group and died on day 5 after infection with P.
haemolytica.
Microbiology. P. haemolytica type Al was isolated from pneumonic areas of the lung in two of the eight vaccinated lambs. In contrast, the bacteria were isolated from pneumonic lung tissue from seven of eight lambs in group 2 treated with antiserum and five of seven lambs in group 3. Mean bacterial counts in pneumonic tissue from these lambs in groups 2 and 3 were 1074 (range, 1060 to 109-0) and 1071 (range, 105-9 to 108), respectively, compared with 1064 and 1058 in the two vaccinates. P. haemolytica type Al was isolated from apparently normal lung tissue from four of the eight lambs in group 2 (mean, 105-9; range, 103-7 to 106.5) and two of the seven lambs in group 3 (103-5 and 103-7). Considering both the results of clinical observation and extent of macroscopic lesions, there was no significant difference between groups 2 and 3. In contrast, the severity of disease assessed in this way in the vaccinated group was significantly less (P < 0.01) than in either group 2 or 3.
DISCUSSION
The SSE vaccine of P. haemolyticca type Al has previously been shown to protect against the effects of challenge infection with this serotype (2) . In that experiment, lambs were challenged 2 months after vaccination and, in some instances, two doses of vaccine were given. In the present experiment, protection was demonstrated 1 month after a single vaccination. Control lambs exhibited the clinical signs of respiratory disease and at postmortem, pneumonic lesions were more extensive than in vaccinates. Clearly, a vaccine of this type may be of value in the prophylaxis of pneumonic pasteurellosis, and more extensive studies have been carried out with a view to its development (2) .
In six of the eight lambs which received antiserum to P. haemolytica, serum antibody titers were similar to those recorded in the vaccinated group at the time of challenge. However, no protective effect could be attributed to the antiserum, a finding which supports the contention that serum antibody is not the only factor important in protecting lambs against respiratory disease associated with P. haemolytica infection. Previous experiments have shown that serum antibodies are transferred into the secretions of the respiratory tract in sheep (8, 9) . Consequently, it is unlikely that any difference between the two groups is due to a difference in the concentration of antibody in the secretions bathing the respiratory mucosa.
It is considered that this experiment implicates cell-mediated immunity as important in the defense mechanisms of sheep which operate to protect against infection with P. haemolytica type Al. The data from the lymphocyte transformation studies showed a specific proliferative INFECT. IMMUN. response in lymphocytes from vaccinates cultured in the presence of P. haemolytica type Al SSE. Such in vitro responses are considered to be a measure of cell-mediated immunity in vivo. Clearly, the proportion of lymphocytes capable of this response appears to increase markedly within a few days of exposure to P. haemolytica type Al as an aerosol. This may be representative of a secondary cellular immune response which is rapid in onset and which could play a valuable part in resisting infection. However, further experiments have indicated that serum from vaccinated lambs has a bacteriostatic effect on P. haemolytica in vitro (H. B. Evans, unpublished data) and, consequently, humoral immunity cannot be entirely discounted. Antibody may have a valuable ancillary role in bacterial clearance in vivo. In addition, it may be significant that no antibodies to P. haemolytica were detectable in the serum from the two lambs that died in the group treated with antiserum. Indeed, humoral immune responses are significant in protecting against infection with P. multocida (13), an encapsulated organism similar to P. haemolytica. Experiments are presently being carried out to clarify further the roles of humoral and cellular immunity to P. haemolytica in sheep.
It could be concluded from the present results that the monitoring of serological responses may not provide a wholly reliable index ofthe efficacy of vaccines. However, it would be unwise to disregard serological data completely since there may be some relationship between the humoral immune response and cell-mediated immunity induced by vaccination. In addition, if cell-mediated immune responses are involved in protection, a measure of them may be of value. Further experiments are necessary to clarify this situation, but these results point to the importance of cell-mediated immunity in resistance of sheep to respiratory disease associated with P. haemolytica.
